506 related articles for article (PubMed ID: 25065299)
21. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels.
Hajela RK; Huntoon KM; Atchison WD
Muscle Nerve; 2015 Feb; 51(2):176-84. PubMed ID: 24862203
[TBL] [Abstract][Full Text] [Related]
22. Paraneoplastic Lambert-Eaton myasthenic syndrome: a diagnostic challenge.
Viveiros L; Martins SR; Pires SX; Neves J
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36707096
[TBL] [Abstract][Full Text] [Related]
23. Lambert-Eaton myasthenic syndrome during anesthesia: a report of 37 patients.
Weingarten TN; Araka CN; Mogensen ME; Sorenson JP; Marienau ME; Watson JC; Sprung J
J Clin Anesth; 2014 Dec; 26(8):648-53. PubMed ID: 25468580
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.
Wang C; Chen S; Feng B; Guan Y
Muscle Nerve; 2014 Mar; 49(3):325-8. PubMed ID: 24464710
[TBL] [Abstract][Full Text] [Related]
25. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.
Sabater L; Titulaer M; Saiz A; Verschuuren J; Güre AO; Graus F
Neurology; 2008 Mar; 70(12):924-8. PubMed ID: 18032743
[TBL] [Abstract][Full Text] [Related]
26. Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure.
Jiang JR; Shih JY; Wang HC; Wu RM; Yu CJ; Yang PC
J Formos Med Assoc; 2002 Dec; 101(12):871-4. PubMed ID: 12632823
[TBL] [Abstract][Full Text] [Related]
27. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS.
Titulaer MJ; Maddison P; Sont JK; Wirtz PW; Hilton-Jones D; Klooster R; Willcox N; Potman M; Sillevis Smitt PA; Kuks JB; Roep BO; Vincent A; van der Maarel SM; van Dijk JG; Lang B; Verschuuren JJ
J Clin Oncol; 2011 Mar; 29(7):902-8. PubMed ID: 21245427
[TBL] [Abstract][Full Text] [Related]
28. Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.
Ginebaugh SP; Badawi Y; Laghaei R; Mersky G; Wallace CJ; Tarr TB; Kaufhold C; Reddel S; Meriney SD
J Neurophysiol; 2023 May; 129(5):1259-1277. PubMed ID: 37073966
[TBL] [Abstract][Full Text] [Related]
29. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
Titulaer MJ; Klooster R; Potman M; Sabater L; Graus F; Hegeman IM; Thijssen PE; Wirtz PW; Twijnstra A; Smitt PA; van der Maarel SM; Verschuuren JJ
J Clin Oncol; 2009 Sep; 27(26):4260-7. PubMed ID: 19667272
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
[TBL] [Abstract][Full Text] [Related]
31. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
Meriney SD; Tarr TB; Ojala KS; Wu M; Li Y; Lacomis D; Garcia-Ocaña A; Liang M; Valdomir G; Wipf P
Ann N Y Acad Sci; 2018 Jan; 1412(1):73-81. PubMed ID: 29125190
[TBL] [Abstract][Full Text] [Related]
32. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
Oh SJ
Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
[TBL] [Abstract][Full Text] [Related]
33. Relapse of both small cell lung cancer and Lambert-Eaton myasthenic syndrome after a 13-year disease-free survival period.
Asano F; Watanabe K; Shinkai M; Tei Y; Mishina K; Tanabe M; Ishii H; Shinoda M; Shimokawaji T; Kudo M; Kaneko T
Chin J Cancer; 2016 Jul; 35(1):63. PubMed ID: 27370896
[TBL] [Abstract][Full Text] [Related]
34. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies.
Sanders DB
Ann Neurol; 1995 May; 37 Suppl 1():S63-73. PubMed ID: 8968218
[TBL] [Abstract][Full Text] [Related]
35. SOX-1 antibodies positive Lambert-Eaton myasthenic syndrome with occult small cell lung cancer: A case report.
Zhao L; He H; Han W; Meng Y; Kang L; Chen Y
Clin Respir J; 2024 Mar; 18(3):e13740. PubMed ID: 38497229
[TBL] [Abstract][Full Text] [Related]
36. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
Flink MT; Atchison WD
J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
[TBL] [Abstract][Full Text] [Related]
37. [Lambert-Eaton myasthenic syndrome--a rare manifestation of paraneoplastic syndrome in ovarian cancer--case report].
Zivaljević M; Popović S; Vujkov T
Med Pregl; 2005; 58(9-10):495-7. PubMed ID: 16526254
[TBL] [Abstract][Full Text] [Related]
38. Anti-SOX1 antibody-positive paraneoplastic neurological syndrome presenting with Lambert-Eaton myasthenic syndrome and small cell lung cancer: A case report.
Li C; Wang X; Sun L; Deng H; Han Y; Zheng W
Thorac Cancer; 2020 Feb; 11(2):465-469. PubMed ID: 31880403
[TBL] [Abstract][Full Text] [Related]
39. Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism.
Gable KL; Massey JM
Semin Neurol; 2015 Aug; 35(4):340-6. PubMed ID: 26502758
[TBL] [Abstract][Full Text] [Related]
40. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder.
Vincent A; Lang B; Newsom-Davis J
Trends Neurosci; 1989 Dec; 12(12):496-502. PubMed ID: 2480664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
